Mon.Feb 05, 2024

article thumbnail

COVID-19 Vaccination Rates Significantly Lower in Patients With Sickle Cell Disease

Drug Topics

Patients with SCD are more vulnerable to hospitalization due, in part, to SCD’s impact on the spleen, which filters infections in the blood and is a crucial organ for the immune system.

article thumbnail

Study Results Highlight Importance of Overcoming Stigma When Addressing Brain Health

Pharmacy Times

The study authors note that to effectively implement tools, processes, and strategies within practices, the stigma surrounding cognitive impairment must be addressed.

144
144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

‘Where you live shouldn’t determine how you get cancer’: An oncologist on global disparities

STAT

The prediction is dire: Cancer cases around the world are expected to surge 77% by 2050, a new report from the World Health Organization estimates. That attention-grabbing statistic, based on an analysis of 185 countries, cites a growing, aging population and factors including tobacco, alcohol, obesity, and pollution. Perhaps the most damning part of the report reveals the disparities determined by income.

144
144
article thumbnail

Data science in healthcare

pharmaphorum

Data science in healthcare is transforming the industry, from drug discovery to patient care. Learn about the role of data, artificial intelligence (AI), and the impact of initiatives like the NHS Datastore in revolutionising healthcare outcomes.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down

STAT

Amgen is trying a unique strategy with its obesity drug candidate: testing whether it can wean patients toward lower or less frequent doses over time. Very early data hints that Amgen’s candidate, called MariTide, may provide longer-lasting weight loss than highly popular obesity drugs on the market like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

143
143
article thumbnail

Increase in STIs Among Adolescents Witnessed During COVID-19 Pandemic

Drug Topics

As a result of an increase in adolescent inpatient visits with a sexually transmitted infection (STI) diagnosis in 2020, further work is needed to improve STI care, particularly for this demographic.

98

More Trending

article thumbnail

Pharmacist-led Primary Care Team Improves Clinical Outcomes in Severe Mental Illness

Pharmacy Times

This approach may help prevent premature deaths attributed to preventable or treatable cardiovascular disease.

145
145
article thumbnail

Medical devices with screens aren’t accessible to the blind. Congress has chance to change that

STAT

Katie Keim was diagnosed with type 1 diabetes in 1967 when she was eight, well before the era of insulin pumps or even reliable home testing. The condition started eating away at her vision 20 years later. By the time she was 36, her sight was completely gone.  Keim had lived an independent life as a child despite her illness. Her summers were spent exploring oceans with her family, not at diabetic summer camps.

FDA 138
article thumbnail

Cardiovascular Outcomes in Patients Intolerant to Statins Treated with Bempedoic Acid

Pharmacy Times

In December 2023, the FDA granted expanded indications for bempedoic acid and bempedoic acid plus ezetimibe in the treatment of primary hyperlipidemia.

FDA 120
article thumbnail

Texas Medicaid agrees to fully cover gene therapy for Afghan refugees’ infant

STAT

After a months-long fight with Texas Medicaid over coverage of a gene therapy, Afghan refugees now have a chance to save their infant son. After initially balking , Texas officials have agreed to pay for the costly treatment, the boy’s family and his doctor told STAT. At the end of last week, N. Pashai’s cell phone rang. It was from a Minnesota area code.

Hospitals 137
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

In a 'spectacular collapse,' Cano Health files for bankruptcy

Fierce Healthcare

Cano Health today announced its intentions for file for bankruptcy in an effort to stay afloat after incurring nearly $1 billion in debt. | Cano said that it has secured a $150 million commitment in debtor-in-possession financing from some of its lenders, which is subject to court approval.

115
115
article thumbnail

STAT+: Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production

STAT

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.   Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.

article thumbnail

Astellas' sales expectations are up for Padcev, down for Veozah

Fierce Pharma

Less than two months after the FDA approved the combination treatment of Astellas and Pfizer’s Padcev and Merck’s Keytruda in first-line bladder cancer, the Japanese company has

FDA 118
article thumbnail

A scholar of the patient ‘revolution’ tracks the arc from powerlessness to influence

STAT

At the end of each chapter in “Rebel Health: A Field Guide to the Patient-Led Revolution in Medical Care,” there’s a box. It summarizes the chapter, distilling what a reader just encountered into easy-to-digest bullet points. The author, Susannah Fox, admits she stole that idea from “The Long Covid Survival Guide,” which was written by patients for patients.

134
134
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Novartis CEO’s 2023 pay rises 21% as Roche's helmsman nets $11M in his first year

Fierce Pharma

After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. | After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.

Packaging 120
article thumbnail

STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?

STAT

Sixteen billion dollars is a lot of money. But Monday’s announcement that the parent company of Novo Nordisk, the maker of the weight loss drug Wegovy, plans to buy Catalent , a company to which drugmakers outsource manufacturing, is probably even more important than it seems. The deal, done in part so that Novo can rapidly ramp up its ability to manufacture Wegovy, is a massive statement of optimism about the sales potential of that medication and weight loss drugs like it, known as GLP-

Vaccines 125
article thumbnail

Pre-Existing Depression, Anxiety Linked With Increased Risk of Insomnia After COVID-19 Infection

Drug Topics

Participants of a recent study who had pre-existing depression or anxiety were significantly more likely to develop insomnia.

112
112
article thumbnail

STAT+: Cano Health’s downfall offers a warning for Medicare Advantage

STAT

Private Medicare just isn’t the gold mine it once was. Case in point: Cano Health, a company once valued at $4.4 billion, is now bankrupt. The prospect of bankruptcy had stalked the Miami-based primary care provider for well over a year before its Chapter 11 filing on Sunday. A number of things had gone wrong. First, there was Cano’s rapid growth ahead of its 2021 initial public offering that gave way to a mountain of debt, currently sitting at $1.3 billion.

Insurance 123
article thumbnail

GSK details Blenrep combo data that could bring the multiple myeloma ADC back to life

Fierce Pharma

If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. | If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. multiple myeloma market with its previously withdrawn BMCA-targeted antibody-drug conjugate, Blenrep.

Packaging 116
article thumbnail

STAT+: Devoted Health’s losses in Medicare Advantage persist

STAT

Devoted Health has been one of the most prominent health insurance and provider startups of the past decade — founded and overseen by several alumni of former President Barack Obama’s administration. But it has not turned a profit after five years of selling Medicare Advantage plans to older adults, according to a STAT analysis of Devoted’s financial filings.

article thumbnail

Persistent Childhood Exposure to Passive Smoke From Heated Tobacco Products Can Increase Cardiovascular Risk in Adulthood

Pharmacy Times

These heat-not-burn cigarettes are incorrectly assumed to be healthier than traditional tobacco cigarettes.

132
132
article thumbnail

STAT+: New Medicare Advantage rule is boon for providers, drag on insurers

STAT

Starting this year, private Medicare plans have to cover their members’ hospitalizations at the higher inpatient rate if their doctors predict they’ll have to stay beyond two midnights. It’s the same rule — appropriately called the two-midnight rule — that traditional Medicare has followed for a decade. After it came out that Medicare Advantage plans were routinely denying coverage for necessary services , the federal government decided they ought to be held to

Insurance 120
article thumbnail

Rural providers optimistic about financial stability, plan to expand services, Wipfli survey finds

Fierce Healthcare

Rural providers optimistic about financial stability, plan to expand services, Wipfli survey finds agliadkovskaya Mon, 02/05/2024 - 15:34

122
122
article thumbnail

STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion

STAT

Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline of cancer drugs for 2.7 billion euros, or $2.9 billion. The Swiss drugmaker will pay 68 euros, or around $73, per share, nearly twice Morphosys’s average trading price over the last month. At the center of the deal is pelabresib, a blood cancer pill that in November posted mixed results in a Phase 3 trial.

111
111
article thumbnail

AbbVie’s new drugs keep post-Humira prospects on track

pharmaphorum

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

105
105
article thumbnail

Regeneron is interested in obesity treatments that combat muscle loss

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Today, we talk about two players that want to join the obesity market with updates to the GLP-1 class: Amgen and Regeneron. Also, a draft bill in Congress would restrict U.S. involvement with Chinese biotechs.

104
104
article thumbnail

10 natural remedies for high cholesterol

The Checkup by Singlecare

If your healthcare provider has recently expressed concern about your cholesterol levels, you’re not alone. About 86 million American adults have high cholesterol. Though high cholesterol does not usually cause symptoms, it can lead to high blood pressure, heart disease, stroke, and heart attack if left untreated. Fortunately, lifestyle changes—diet, in particular—can help you lower your cholesterol naturally. 10 home remedies for high cholesterol Along with a personalized action plan from a hea

Packaging 105
article thumbnail

Let the Medicare Advantage lobbying begin

STAT

You’re reading the web version of Health Care Inc.,  STAT’s weekly newsletter  following the flow of money in medicine.  Sign up  to get it in your inbox every Monday.  Taking stock of the 2025 MA proposals If there’s one thing to take away from CMS’ newest proposals for Medicare Advantage plans, it’s that the Biden administration didn’t really want to rock the boat in an election year.

Insurance 103
article thumbnail

Novo Nordisk tackles supply issues with $11bn Catalent deal

pharmaphorum

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes and obesity drugs. The deal includes $11 billion upfront to buy the fill-finish sites that Novo Nordisk said will enable “an expansion of the manufacturing capacity at scale and speed while providing future optionality and flexibility for Novo Nordisk’s existing supply network.

105
105
article thumbnail

STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of phone calls, online meetings, and deadlines has predictably returned. But you knew this would happen. After all, the world keeps spinning, at least for now. So time to give it a nudge in a better direction with a cup of delicious stimulation.

103
103
article thumbnail

Astellas raises Padcev forecasts on bladder cancer data

pharmaphorum

A bladder cancer study prompts Astellas to lift peak sales prediction for Padcev, although its menopause therapy Veozah isn’t ramping up as hoped.

116
116
article thumbnail

With half of alcoholics refusing to abstain, Kinnov's new drug to fight addiction couldn't come soon enough

Outsourcing Pharma

No new treatments to combat the major public health issue of alcohol use disorder (AUD), have been brought to market for ten years - and with half of heavy drinkers refusing the abstinence route, new drug could be the answer.

104
104
article thumbnail

WuXi AppTec defends against 'blanket allegations' as US legislation casts shadow over certain Chinese drugmakers

Fierce Pharma

As new legislation stands to threaten the U.S. business of certain Chinese biopharma companies, CDMO giant WuXi AppTec has stepped in to make a case for itself. | The company's executives inked an open letter after the recent BIOSECURE act flagged WuXi AppTec and other Chinese drugmakers as potential national security threats.

109
109
article thumbnail

Adalimumab Biosimilar Shows Efficacy in Noninfectious Uveitis

Pharmacy Times

Switching from adalimumab originator to SB5 did not cause clinically significant differences in treatment efficacy and safety for patients with noninfectious uveitis.

139
139